$3.16 Billion is the total value of BRAIDWELL LP's 86 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GUARDANT HEALTH INCnote 11/1 | $185,764,510 | -3.8% | 268,252,000 | 0.0% | 5.87% | -7.0% | ||
| NOVOCURE LTDnote 11/0 | $118,012,579 | -0.1% | 135,834,000 | 0.0% | 3.73% | -3.4% | ||
| ASCENDIS PHARMA A/Snote 2.250% 4/0 | $113,770,000 | +0.5% | 124,000,000 | 0.0% | 3.60% | -2.8% | ||
| EXACT SCIENCES CORPnote 0.375% 3/0 | $113,721,100 | -15.6% | 131,000,000 | 0.0% | 3.59% | -18.3% | ||
| NANOSTRING TECHNOLOGIES INCnote 2.625% 3/0 | $112,369,466 | -2.6% | 145,520,000 | 0.0% | 3.55% | -5.8% | ||
| NEVRO CORPnote 2.750% 4/0 | $102,018,584 | +1.1% | 109,251,000 | 0.0% | 3.22% | -2.2% | ||
| IONIS PHARMACEUTICALS INCnote 4/0 | $51,764,310 | +3.5% | 52,740,000 | 0.0% | 1.64% | +0.1% | ||
| TRAVERE THERAPEUTICS INCnote 2.500% 9/1 | $48,220,279 | -4.5% | 56,031,000 | 0.0% | 1.52% | -7.6% | ||
| KARYOPHARM THERAPEUTICS INCnote 3.000%10/1 | $40,943,996 | -4.8% | 65,976,000 | 0.0% | 1.29% | -8.0% | ||
| INSMED INCnote 1.750% 1/1 | $39,723,222 | +4.5% | 39,963,000 | 0.0% | 1.26% | +1.0% | ||
| NVRO | NEVRO CORP | $34,141,793 | -24.4% | 1,776,368 | 0.0% | 1.08% | -26.8% | |
| NEOGENOMICS INCnote 1.250% 5/0 | $26,250,000 | -0.2% | 28,000,000 | 0.0% | 0.83% | -3.4% | ||
| TRAVERE THERAPEUTICS INCnote 2.250% 3/0 | $18,393,480 | -19.3% | 28,350,000 | 0.0% | 0.58% | -22.0% | ||
| CGEM | CULLINAN ONCOLOGY INC | $17,275,228 | -15.9% | 1,908,865 | 0.0% | 0.55% | -18.6% | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $16,466,588 | -28.4% | 12,107,785 | 0.0% | 0.52% | -30.9% | |
| INVITAE CORPnote 2.000% 9/0 | $14,850,082 | -0.8% | 16,781,000 | 0.0% | 0.47% | -4.1% | ||
| INTEGRA LIFESCIENCES HLDGS Cnote 0.500% 8/1 | $13,296,500 | -0.1% | 14,500,000 | 0.0% | 0.42% | -3.4% | ||
| CMPX | COMPASS THERAPEUTICS INC | $11,729,918 | -38.1% | 5,954,273 | 0.0% | 0.37% | -40.1% | |
| ENTA | ENANTA PHARMACEUTICALS INC | $11,597,923 | -47.8% | 1,038,310 | 0.0% | 0.37% | -49.4% | |
| SGEN | SEAGEN INC | $9,015,739 | +10.2% | 42,497 | 0.0% | 0.28% | +6.7% | |
| REPL | REPLIMUNE GROUP INC | $8,341,467 | -26.3% | 487,520 | 0.0% | 0.26% | -28.6% | |
| ALXO | ALX ONCOLOGY HLDGS INC | $5,999,520 | -36.1% | 1,249,900 | 0.0% | 0.19% | -38.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GUARDANT HEALTH INC | 4 | Q3 2023 | 6.3% |
| EXACT SCIENCES CORP | 4 | Q3 2023 | 4.4% |
| NOVOCURE LTD | 4 | Q3 2023 | 3.9% |
| NANOSTRING TECHNOLOGIES INC | 4 | Q3 2023 | 4.0% |
| NEVRO CORP | 4 | Q3 2023 | 3.4% |
| BRIDGEBIO PHARMA INC | 4 | Q3 2023 | 3.5% |
| ALPHATEC HLDGS INC | 4 | Q3 2023 | 3.6% |
| GLAUKOS CORP | 4 | Q3 2023 | 3.0% |
| VAXCYTE INC | 4 | Q3 2023 | 2.8% |
| XENON PHARMACEUTICALS INC | 4 | Q3 2023 | 2.5% |
View BRAIDWELL LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
View BRAIDWELL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.